Search results
Showing 136 to 148 of 148 results for multiple sclerosis
This quality standard covers preventing, assessing and managing pressure ulcers (bed sores) in adults, young people and children. It includes risk assessment and support to prevent pressure ulcers. It applies to all settings, including hospitals, care homes (with and without nursing care) and people’s own homes.
View quality statements for QS89Show all sections
Sections for QS89
- Introduction
- List of quality statements
- Quality statement 1: Pressure ulcer risk assessment in hospitals and care homes with nursing
- Quality statement 2: Pressure ulcer risk assessment by community nursing services
- Quality statement 3: Pressure ulcer risk reassessment
- Quality statement 4: Skin assessment
- Quality statement 5: Advice on repositioning
- Quality statement 6: Help with repositioning
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....
View recommendations for HTE15Show all sections
Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
Professor Martin Cowie stands down from the NICE board following his appointment to a role at Astra Zeneca
Patients with relapsing remitting multiple sclerosis can now be offered a pill that helps reduce the number of relapses, says NICE.
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
Use NICE quality standards to guide good quality social care, says CQC
Social care services should use NICE guidance and quality standards to help identify and define good quality care, according to the Care Quality Commission (CQC).
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
As NICE publishes its 300th technology appraisal, we look back at the impact they have had on patient care.